Eli Lilly and AstraZeneca announced that they are stopping two global Phase 3 trials of lanabecestat, an amyloid…
Articles by José Lopes, PhD
Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2…
Janssen pulled the plug on a Phase 2b/3 trial and a Phase 2 safety study of its Alzheimer’s disease…
The U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals’ investigational new drug (IND) application to support the…
A form of vitamin B3 was found to prevent brain damage and improve memory and physical function in a new…
Roche soon will start two Phase 3 trials testing gantenerumab, its amyloid-targeting treatment candidate, in prodromal, or early, Alzheimer’s…
The safety and efficacy of Roche’s gantenerumab, a treatment candidate for Alzheimer’s, will be tested in two global Phase 3…
The U.S. Food and Drug Administration has revised clinical trial guidelines for Alzheimer’s therapies to help researchers come up with…
Results from a Phase 2 clinical trial show that Nuplazid (pimavanserin) can safely treat, but possibly in the short-term only,…
In another blow to hopes for an effective Alzheimer’s treatment, Merck announced that it is stopping its Phase 3 clinical study…